Roche Holding Feed

2025-10-18 07:00:00 Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

2025-10-17 22:20:00 Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

2025-10-17 12:30:00 CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis 282,45 CHF | -0,25%

2025-10-16 07:00:00 Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025 283,15 CHF | +0,66%

2025-10-13 07:00:00 Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types 291,05 CHF | -1,02%

2025-10-06 07:00:00 Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel 288,00 CHF | +0,19%

2025-10-03 07:05:00 FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer 287,45 CHF | +0,68%

2025-10-03 07:00:00 Change in the Roche Board of Directors 287,45 CHF | +0,68%

2025-10-01 22:30:00 Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash 285,50 CHF | +2,42%

2025-09-30 07:00:00 Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks 258,55 CHF | +1,87%

2025-09-24 08:30:00 Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025 260,60 CHF | -1,81%

2025-09-22 07:00:00 Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer 269,00 CHF | +1,17%

2025-09-19 14:15:00 CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma 265,90 CHF | +1,64%

2025-09-18 07:00:00 Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH 261,60 CHF | +1,34%

2025-09-05 07:00:00 New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD) 275,55 CHF | +0,75%

2025-09-04 08:00:00 Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD) 273,50 CHF | +1,79%

2025-08-30 16:30:00 Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

2025-08-25 20:30:00 Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA 261,60 CHF | -0,08%

2025-08-01 20:00:00 Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

2025-07-28 07:00:00 Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC 262,75 CHF | -0,34%

2025-07-25 13:00:00 Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU 263,65 CHF | -0,08%

2025-07-24 07:00:00 [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starkes Wachstum im ersten Halbjahr 2025 fort: Verkäufe steigen um 7% (CER) 263,85 CHF | +1,44%

2025-07-24 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025 263,85 CHF | +1,44%

2025-07-23 07:10:00 Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease 260,10 CHF | +2,73%

2025-07-23 07:00:00 European Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation 260,10 CHF | +2,73%

2025-07-22 18:45:00 Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine) 260,10 CHF | +2,73%

2025-07-22 18:45:00 Roche Verwaltungsrat schlägt Umtausch von Genussscheinen in Partizipationsscheine vor 260,10 CHF | +2,73%

2025-07-21 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease 254,65 CHF | -0,95%

2025-06-30 07:00:00 Changes to the Roche Enlarged Corporate Executive Committee 261,90 CHF | -0,55%

2025-06-23 07:00:00 Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A 257,90 CHF | -1,11%

2025-06-20 17:45:00 Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma 260,80 CHF | +1,40%

2025-06-16 07:00:00 Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease 263,85 CHF | -2,17%

2025-06-15 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

2025-06-04 07:00:00 Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA) 268,10 CHF | +1,02%

2025-06-03 07:00:00 Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer 265,40 CHF | +0,04%

2025-05-31 14:05:00 New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

2025-05-30 07:00:00 Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis 264,00 CHF | +1,11%

2025-05-23 15:00:00 CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer 257,00 CHF | -0,45%

2025-05-23 07:10:00 Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology 257,00 CHF | -0,45%

2025-05-23 07:00:00 New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients 257,00 CHF | -0,45%

2025-05-22 17:45:00 FDA approves Roche’s Susvimo for diabetic retinopathy 257,00 CHF | -0,45%

2025-05-20 20:40:00 Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma 262,65 CHF | -1,00%

2025-05-14 22:00:00 Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis 253,40 CHF | -1,71%

2025-05-13 07:00:00 Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer 260,50 CHF | +0,72%

2025-05-06 07:00:00 Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity 272,20 CHF | +0,04%

2025-04-30 07:00:00 CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings 269,00 CHF | +0,73%

2025-04-25 07:00:00 New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission 261,10 CHF | -0,15%

2025-04-23 07:00:00 Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS) 258,45 CHF | +1,95%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Roche Holding

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden